Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 22, 2026

Americans would get ‘universal high income’ via steady federal checks under Elon Musk’s new proposal. Will it happen?

View original at finance.yahoo.com
Americans would get ‘universal high income’ via steady federal checks under Elon Musk’s new proposal. Will it happen? Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Universal HIGH INCOME via checks issued by the Federal government is the best way to deal with unemployment caused by AI

    60% confidence

  • Roughly 30,000 additional jobs have already been lost to AI in early 2026

    60% confidence

  • AI was linked to nearly 55,000 job cuts in the U.S. in 2025

    60% confidence

  • Advances in automation and productivity could dramatically increase the supply of goods and services, potentially offsetting inflationary pressure from increased money circulation

    60% confidence

  • AI and robotics will produce goods and services far in excess of the increase in the money supply, so there will not be inflation

    60% confidence

Data points we hold from this source

Elon Musk · social media post comments46000 comments
Elon Musk · social media post likes195000 likes
Elon Musk · social media post views68000000 views
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com